Santen Pharmaceutical has been granted a patent for an implantable eye device featuring an elongate duct with two parallel lumens and a second portion with outward-flaring tubular segments. This design allows fluid communication through a common lumen with multiple outlets, facilitating effective fluid flow within the eye. GlobalData’s report on Santen Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Santen Pharmaceutical, Nanoparticle drug conjugates was a key innovation area identified from patents. Santen Pharmaceutical's grant share as of July 2024 was 44%. Grant share is based on the ratio of number of grants to total number of patents.
Implantable eye device with fluid flow capabilities
The patent US12011391B2 describes an innovative implantable device designed for use in the eye, specifically for facilitating fluid drainage. The device features an elongate duct portion with two parallel lumens extending from a distal end to a neck, which connects to a second portion comprising tubular segments that flare outwardly to form a tubular loop. This loop creates an enclosed lumen with multiple distinct outlets that communicate with the lumens of the duct portion, allowing for fluid flow. Notably, the entire structure is designed as a unitary component, ensuring integrity prior to implantation. The materials specified for the device include SIBS (poly(styrene-block-isobutylene-block-styrene)), which is known for its biocompatibility.
In addition to its structural features, the patent outlines a method for utilizing the device in treating eye conditions. The distal end of the duct portion is positioned in the anterior chamber of the eye, while the tubular loop is placed in a drainage cavity or bleb formed by ocular tissue. This configuration enables the device to facilitate the flow of aqueous humor from the anterior chamber into the drainage cavity. The design includes surfaces that interface with ocular tissue, enhancing its functionality. Furthermore, the patent describes a drug delivery aspect, where the device can be integrated with a fluid reservoir for therapeutic agents, allowing for controlled delivery through the device's lumens. The reservoir is designed to be self-sealing and can be punctured for filling, adding to the device's versatility in ocular treatments.
To know more about GlobalData’s detailed insights on Santen Pharmaceutical, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
